RESUMEN
BACKGROUND: Long-acting muscarinic antagonist/long-acting ß2-agonist (LAMA/LABA, also known as dual bronchodilator) and inhaled corticosteroid/LABA (ICS/LABA) are the cornerstone of maintenance treatment for stable chronic obstructive pulmonary disease (COPD) patients. We aimed to comprehensively compare the efficacy and safety of the two maintenance treatment in COPD patients. METHODS: We searched the database Embase, Cochrane Library, PubMed, and Clinical Trials.gov systematically (from inception until September 2020). Randomized controlled trials (RCTs) comparing dual bronchodilator with ICS/LABA in the treatment of COPD were included. Efficacy and safety endpoints were pooled as mean differences (MDs) and risk ratios (RRs) with 95% confidence intervals (CIs). This meta-analysis was registered with PROSPERO prospectively # CRD42020203314). RESULTS: Fourteen RCTs including 21,496 patients were included. Dual bronchodilator showed a greater improvement in both trough FEV1 (MD = 0.06 L, 95% CI: 0.04-0.07, P < 0.001) and FVC (FVC: MD = 0.12 L, 95% CI: 0.07-0.16, P < 0.001), and a lower risk of pneumonia (RR = 0.62, 95% CI: 0.53-0.72, P < 0.001) in patients with COPD. There were no significant differences neither in the improvement of exacerbations, symptoms, and quality of life, nor in the incidence of cardiovascular events, serious adverse events, all-cause mortality, and withdrawals due to adverse events of treatment between these two maintenance treatments. CONCLUSIONS: Dual bronchodilator is superior to ICS/LABA in improving lung function and is associated with a lower risk of pneumonia in patients with COPD. There are no significant differences in other efficacy and safety profiles between these two maintenance treatments.
Asunto(s)
Corticoesteroides/uso terapéutico , Antagonistas de Receptores Adrenérgicos beta 2/uso terapéutico , Antagonistas Muscarínicos/uso terapéutico , Enfermedad Pulmonar Obstructiva Crónica/tratamiento farmacológico , Administración por Inhalación , Humanos , Neumonía/etiología , Enfermedad Pulmonar Obstructiva Crónica/complicaciones , Ensayos Clínicos Controlados Aleatorios como Asunto , RiesgoRESUMEN
Medicinal plants have been identified and used as primary sources in prevention and treatment of pulmonary diseases (mainly obstructive pulmonary diseases) from ancient times due to various pharmacological activities. In this review, the stimulatory effects of extracts, some fractions and constituents of medicinal plants on ß2-adrenoceptors which could be used as possible therapeutic agents in the future were reviewed. Various databases including; Medline, PubMed, ScienceDirect, Scopus, and Google Scholar were searched using stimulatory effect, ß2-adrenoceptors, possible mechanism, tracheal smooth muscle (TSM), medicinal plants and their constituents as keywords from 1985 to 2017. All studied plants including; Nigella sativa, Rosa damascena, Thymus vulgaris, Carum copticom, Carum carvi, Zataria multiflora, Crocus sativus, Cuminum cyminum, Liomnia acidissima, Portulaca oleraceae, Satureja hortensis, Ephedra sinica and Achillea millefolium showed relaxant effect on tracheal smooth muscle with a stimulatory effect on ß2-adrenoceptors mechanism. The studied plants and their constituents could be of therapeutic value in clinical practice as a bronchodilatory drug by ß2-adrenoceptors stimulatory mechanism for treatment of obstructive pulmonary diseases.
Asunto(s)
Músculo Liso/efectos de los fármacos , Extractos Vegetales/farmacología , Receptores Adrenérgicos beta 2/fisiología , Tráquea/efectos de los fármacos , Agonistas de Receptores Adrenérgicos beta 2/farmacología , Antagonistas de Receptores Adrenérgicos beta 2/farmacología , Animales , Humanos , Músculo Liso/fisiología , Plantas Medicinales , Tráquea/fisiologíaRESUMEN
Doping is the use of a substance that artificially increases an individual's physical ability for competition purpose. Products and methods used in doping are not without risk, especially at cardiovascular level. Here we review the most common doping substances in sport and their cardiovascular consequences.
Asunto(s)
Enfermedades Cardiovasculares/inducido químicamente , Doping en los Deportes , Antagonistas de Receptores Adrenérgicos beta 2/efectos adversos , Anabolizantes/efectos adversos , Transfusión de Sangre Autóloga/efectos adversos , Cannabinoides/efectos adversos , Enfermedades Cardiovasculares/prevención & control , Estimulantes del Sistema Nervioso Central/efectos adversos , Diuréticos/efectos adversos , Eritropoyetina/efectos adversos , Glucocorticoides/efectos adversos , Antagonistas de Hormonas/efectos adversos , HumanosRESUMEN
Technological progress and the introduction of modern therapeutic methods are constantly changing contemporary orthodontics. More and more orthodontic patients are working adults, who expect satisfactory therapeutic effects as soon as possible, increasing the importance of methods accelerating tooth movement. The aim of this study was to review the current literature regarding methods of accelerating tooth movement and reducing the duration of the active phase of therapy. The literature was collected from the PubMed and EBSCO databases using "accelerated orthodontic tooth movement" as the search key words. The methods described were categorized as conservative and surgical. The pharmacological agents used in conservative treatment, such as growth hormone, parathyroid hormone, thyroxine, and vitamin D, are especially worth mentioning. They stimulate osteoclasts to increase resorption through a variety of mechanisms. Effective methods also include physical stimuli, e.g., vibrations or photobiomodulation. Most studies describing the effects of pharmacological agents were based on animal subjects and they may therefore lack clinical relevancy. Corticotomy and its modifications based on the regional acceleratory phenomenon (RAP) might prove to be a useful augmentation of orthodontic treatment, especially in adults, including patients with periodontal disease.
Asunto(s)
Movilidad Dentaria , Técnicas de Movimiento Dental/métodos , Antagonistas de Receptores Adrenérgicos beta 2/uso terapéutico , Proceso Alveolar/cirugía , Hueso Cortical/cirugía , Campos Electromagnéticos , Hormona del Crecimiento/uso terapéutico , Humanos , Terapia por Luz de Baja Intensidad , Magnetoterapia , Hormona Paratiroidea/uso terapéutico , Piezocirugía , Tiroxina/uso terapéutico , Vibración/uso terapéutico , Vitamina D/uso terapéutico , Vitaminas/uso terapéuticoRESUMEN
Numerous studies have shown that exacerbation rates in COPD can be significantly reduced by long acting beta-2-agonists (LABA), long acting anticholinergic agents (LAMA) and inhaled steroids (ICS). Elaborate and extensive investigations however failed to prove that the reduction in exacerbation rates leads to life prolongation. As opposed to this, numerous studies have shown a reduction in life expectancy with increasing number and severity of exacerbations.This review aimed at comparing these studies and to elaborate the relevance and reduction of exacerbations rates by LABA, LAMA and ICS application through effect size calculation by means of Cohens' d. These studies display a common pattern. The reduction of exacerbation rates is only being achieved for less severe exacerbations (Cohens' d max. 0.21). For more severe exacerbations and for the comparison of different substances Cohens' d remains below 0.1, indicating that the effect of the medications is practically irrelevant. The impact of LABA's, LAMA's and ICS on exacerbation rates in COPD patients is obviously overrated.
Asunto(s)
Corticoesteroides/uso terapéutico , Antagonistas de Receptores Adrenérgicos beta 2/uso terapéutico , Antagonistas Colinérgicos/uso terapéutico , Progresión de la Enfermedad , Enfermedad Pulmonar Obstructiva Crónica/tratamiento farmacológico , Administración por Inhalación , Corticoesteroides/efectos adversos , Antagonistas de Receptores Adrenérgicos beta 2/efectos adversos , Antagonistas Colinérgicos/efectos adversos , Ensayos Clínicos como Asunto , Preparaciones de Acción Retardada , Alemania , Humanos , Pronóstico , Enfermedad Pulmonar Obstructiva Crónica/diagnósticoRESUMEN
BACKGROUND: Based on the traditional application of traditional Chinese Medicines (TCMs), Ephedra Herba (EH) is used to cure cold fever by inducing sweating, whereas Ephedra Radix (ER) is used to treat hyperhidrosis. Although they come from the same plant, Ephedra sinica Stapf, but have play opposing roles in clinical applications. EH is known to contain ephedrine alkaloids, which is the driver of the physiological changes in sweating, heart rate and blood pressure. However, the active pharmacological ingredients (APIs) of ER and the mechanisms by which it restricts sweating remain unknown. PURPOSE: The current work aims to discover the hidroschesis APIs from ER, as well as to establish its action mechanism. METHODS: UPLC-Q/TOF-MS, PCA, and heat map were utilized for identifying the differences between EH and ER. HPLC integrated with a ß2-adrenoceptor (ß2-AR) activity luciferase reporter assay system was used to screen active inhibitors; molecular docking and a series of biological assays centered on ß2-AR-related signaling pathways were evaluated to understand the roles of APIs. RESULTS: The opposite effect on sweating of EH and ER can be attributed to the APIs of amphetamine-type alkaloids and flavonoid derivatives. Mahuannin B is an effective anti-hydrotic agent, inhibiting the production of cAMP via suppression of adenylate cyclase (AC) activity. CONCLUSION: The effects of EH and ER on sweat and ß2-AR-related signaling pathway are opposite due to different alkaloids and flavonoids of APIs in EH and ER. The present work not only sheds light on the hidroschesis action of mahuannin B, but also presents a potential target of AC in the treatment of hyperhidrosis.
Asunto(s)
Inhibidores de Adenilato Ciclasa/farmacología , Alcaloides/farmacología , AMP Cíclico/metabolismo , Medicamentos Herbarios Chinos/farmacología , Ephedra/química , Flavonoides/farmacología , Receptores Adrenérgicos beta 2/metabolismo , Inhibidores de Adenilato Ciclasa/química , Antagonistas de Receptores Adrenérgicos beta 2/química , Antagonistas de Receptores Adrenérgicos beta 2/farmacología , Alcaloides/química , Animales , Cromatografía Líquida de Alta Presión , Evaluación Preclínica de Medicamentos/métodos , Medicamentos Herbarios Chinos/química , Ephedra sinica/química , Efedrina/farmacología , Flavonoides/química , Masculino , Ratones , Simulación del Acoplamiento Molecular , Receptores Adrenérgicos , Transducción de Señal/efectos de los fármacos , Especificidad de la Especie , Sudoración/efectos de los fármacosRESUMEN
Beige adipocytes emerge postnatally within the white adipose tissue in response to certain environmental cues, such as chronic cold exposure. Because of its highly recruitable nature and relevance to adult humans, beige adipocytes have gained much attention as an attractive cellular target for antiobesity therapy. However, molecular circuits that preferentially promote beige adipocyte biogenesis remain poorly understood. We report that a combination of mild cold exposure at 17°C and capsinoids, a nonpungent analog of capsaicin, synergistically and preferentially promotes beige adipocyte biogenesis and ameliorates diet-induced obesity. Gain- and loss-of-function studies show that the combination of capsinoids and cold exposure synergistically promotes beige adipocyte development through the ß2-adrenoceptor signaling pathway. This synergistic effect on beige adipocyte biogenesis occurs through an increased half-life of PRDM16, a dominant transcriptional regulator of brown/beige adipocyte development. We document a previously unappreciated molecular circuit that controls beige adipocyte biogenesis and suggest a plausible approach to increase whole-body energy expenditure by combining dietary components and environmental cues.
Asunto(s)
Aclimatación , Adipocitos Beige/fisiología , Adipogénesis , Fármacos Antiobesidad/uso terapéutico , Capsaicina/análogos & derivados , Suplementos Dietéticos , Obesidad/prevención & control , Adipocitos Beige/citología , Adipocitos Beige/efectos de los fármacos , Adipocitos Beige/patología , Adipogénesis/efectos de los fármacos , Agonistas de Receptores Adrenérgicos beta 2/farmacología , Agonistas de Receptores Adrenérgicos beta 2/uso terapéutico , Antagonistas de Receptores Adrenérgicos beta 2/farmacología , Antagonistas de Receptores Adrenérgicos beta 2/toxicidad , Animales , Fármacos Antiobesidad/agonistas , Fármacos Antiobesidad/antagonistas & inhibidores , Capsaicina/agonistas , Capsaicina/antagonistas & inhibidores , Capsaicina/química , Capsaicina/uso terapéutico , Células Cultivadas , Frío , Proteínas de Unión al ADN/química , Proteínas de Unión al ADN/genética , Proteínas de Unión al ADN/metabolismo , Metabolismo Energético/efectos de los fármacos , Regulación de la Expresión Génica/efectos de los fármacos , Hidrogenación , Masculino , Ratones Endogámicos C57BL , Ratones Transgénicos , Obesidad/inducido químicamente , Obesidad/metabolismo , Obesidad/patología , Consumo de Oxígeno/efectos de los fármacos , Estabilidad Proteica/efectos de los fármacos , Distribución Aleatoria , Receptores Adrenérgicos beta 2/química , Receptores Adrenérgicos beta 2/genética , Receptores Adrenérgicos beta 2/metabolismo , Transducción de Señal/efectos de los fármacos , Factores de Transcripción/química , Factores de Transcripción/genética , Factores de Transcripción/metabolismoRESUMEN
BACKGROUND: Rikkunshito (RKT) is a gastroprotective herbal medicine. In this study, we investigated the role of RKT in the relaxation of the gastric body (fundus and corpus) and antrum. METHODS: We used Suncus murinus, a unique small model animal with similar gastrointestinal motility to humans and dogs. RKT was added at 0.1, 1.0, and 5.0 mg/mL to induce relaxation in vitro; the outcome measure was the intensity of relaxation. The number of spontaneous antral contractions in the absence or the presence of RKT was also counted. KEY RESULTS: Rikkunshito induced the relaxation of the gastric body and antrum and decreased the number of spontaneous antral contractions in a dose-dependent manner. The responses to RKT (1.0 mg/mL) were not affected by pretreatment with atropine, N-nitro-l-arginine methyl ester, ritanserin, or ondansetron. On the other hand, timolol almost completely reversed the relaxation induced by RKT (1.0 mg/mL) on the gastric body and antrum and the occurrence of the spontaneous antral contractions. Both butoxamine, a ß(2) -adrenoreceptor antagonist, and L 748337, a ß(3) -adrenoreceptor antagonist, but not CGP 20712, a ß(1) -adrenoreceptor antagonist, significantly reversed the RKT-induced (1.0 mg/mL) gastric relaxation. CONCLUSIONS & INFERENCES: These results indicate that RKT stimulates and modulates gastric relaxation through ß(2) - and ß(3) -adrenergic, but not ß(1) -adrenergic, pathways in S. murinus.
Asunto(s)
Medicamentos Herbarios Chinos/farmacología , Fundus Gástrico/efectos de los fármacos , Contracción Muscular/efectos de los fármacos , Relajación Muscular/efectos de los fármacos , Músculo Liso/efectos de los fármacos , Antro Pilórico/efectos de los fármacos , Musarañas , Antagonistas de Receptores Adrenérgicos beta 1/farmacología , Antagonistas de Receptores Adrenérgicos beta 2/farmacología , Antagonistas de Receptores Adrenérgicos beta 3/farmacología , Antagonistas Adrenérgicos beta/farmacología , Aminofenoles/farmacología , Animales , Butoxamina/farmacología , Motilidad Gastrointestinal/efectos de los fármacos , Imidazoles/farmacología , Técnicas In Vitro , Receptores Adrenérgicos beta 1/efectos de los fármacos , Receptores Adrenérgicos beta 2/efectos de los fármacos , Receptores Adrenérgicos beta 3/efectos de los fármacos , Estómago/efectos de los fármacos , Sulfonamidas/farmacología , Timolol/farmacologíaRESUMEN
The spectacular advances in G-protein-coupled receptor (GPCR) structure determination have opened up new possibilities for structure-based GPCR ligand discovery. The structure-based prediction of whether a ligand stimulates (full/partial agonist), blocks (antagonist), or reduces (inverse agonist) GPCR signaling activity is, however, still challenging. A total of 31 ß1 (ß1R) and ß2 (ß2R) adrenoceptor crystal structures, including antagonist, inverse agonist, and partial/full agonist-bound structures, allowed us to explore the possibilities and limitations of structure-based prediction of GPCR ligand function. We used all unique protein-ligand interaction fingerprints (IFPs) derived from all ligand-bound ß-adrenergic crystal structure monomers to post-process the docking poses of known ß1R/ß2R partial/full agonists, antagonists/inverse agonists, and physicochemically similar decoys in each of the ß1R/ß2R structures. The systematic analysis of these 1920 unique IFP-structure combinations offered new insights into the relative impact of protein conformation and IFP scoring on selective virtual screening (VS) for ligands with a specific functional effect. Our studies show that ligands with the same function can be efficiently classified on the basis of their protein-ligand interaction profile. Small differences between the receptor conformation (used for docking) and reference IFP (used for scoring of the docking poses) determine, however, the enrichment of specific ligand types in VS hit lists. Interestingly, the selective enrichment of partial/full agonists can be achieved by using agonist IFPs to post-process docking poses in agonist-bound as well as antagonist-bound structures. We have identified optimal structure-IFP combinations for the identification and discrimination of antagonists/inverse agonist and partial/full agonists, and defined a predicted IFP for the small full agonist norepinephrine that gave the highest retrieval rate of agonists over antagonists for all structures (with an enrichment factor of 46 for agonists and 8 for antagonists on average at a 1% false-positive rate). This ß-adrenoceptor case study provides new insights into the opportunities for selective structure-based discovery of GPCR ligands with a desired function and emphasizes the importance of IFPs in scoring docking poses.
Asunto(s)
Agonistas de Receptores Adrenérgicos beta 1/metabolismo , Antagonistas de Receptores Adrenérgicos beta 1/metabolismo , Agonistas de Receptores Adrenérgicos beta 2/metabolismo , Antagonistas de Receptores Adrenérgicos beta 2/metabolismo , Biología Computacional/métodos , Receptores Adrenérgicos beta 1/metabolismo , Receptores Adrenérgicos beta 2/metabolismo , Agonistas de Receptores Adrenérgicos beta 1/farmacología , Antagonistas de Receptores Adrenérgicos beta 1/farmacología , Agonistas de Receptores Adrenérgicos beta 2/farmacología , Antagonistas de Receptores Adrenérgicos beta 2/farmacología , Animales , Cristalografía por Rayos X , Evaluación Preclínica de Medicamentos , Humanos , Ligandos , Simulación del Acoplamiento Molecular , Conformación Proteica , Receptores Adrenérgicos beta 1/química , Receptores Adrenérgicos beta 2/químicaRESUMEN
Occluded ligand-binding pockets (LBP) such as those found in nuclear receptors (NR) and G-protein coupled receptors (GPCR) represent a significant opportunity and challenge for computer-aided drug design. To determine free energies maps of functional groups of these LBPs, a Grand-Canonical Monte Carlo/Molecular Dynamics (GCMC/MD) strategy is combined with the Site Identification by Ligand Competitive Saturation (SILCS) methodology. SILCS-GCMC/MD is shown to map functional group affinity patterns that recapitulate locations of functional groups across diverse classes of ligands in the LBPs of the androgen (AR) and peroxisome proliferator-activated-γ (PPARγ) NRs and the metabotropic glutamate (mGluR) and ß2-adreneric (ß2AR) GPCRs. Inclusion of protein flexibility identifies regions of the binding pockets not accessible in crystal conformations and allows for better quantitative estimates of relative ligand binding affinities in all the proteins tested. Differences in functional group requirements of the active and inactive states of the ß2AR LBP were used in virtual screening to identify high efficacy agonists targeting ß2AR in Airway Smooth Muscle (ASM) cells. Seven of the 15 selected ligands were found to effect ASM relaxation representing a 46% hit rate. Hence, the method will be of use for the rational design of ligands in the context of chemical biology and the development of therapeutic agents.
Asunto(s)
Evaluación Preclínica de Medicamentos/métodos , Receptores Acoplados a Proteínas G/química , Receptores Acoplados a Proteínas G/metabolismo , Antagonistas de Receptores Adrenérgicos beta 2/química , Antagonistas de Receptores Adrenérgicos beta 2/farmacología , Animales , Sitios de Unión , Simulación por Computador , Cristalografía por Rayos X , Humanos , Ligandos , Ratones Endogámicos , Modelos Moleculares , Simulación de Dinámica Molecular , Método de Montecarlo , PPAR gamma/química , PPAR gamma/metabolismo , Conformación Proteica , Receptores Adrenérgicos beta 2/química , Receptores Adrenérgicos beta 2/metabolismo , Receptores Androgénicos/química , Receptores Androgénicos/metabolismo , Receptores de Glutamato Metabotrópico/química , Receptores de Glutamato Metabotrópico/metabolismo , Tráquea/efectos de los fármacosRESUMEN
The objective of the present studies was to characterize the pharmacologic properties of GSK-961081 [TD-5959; (R)-1-(3-((2-chloro-4-(((2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethyl)amino)methyl)-5-methoxyphenyl)amino)-3-oxopropyl) piperidin-4-yl [1,1'-biphenyl]-2-ylcarbamate], a novel first-in-class inhaled bifunctional compound possessing both muscarinic antagonist (MA) and ß2-adrenoceptor agonist (BA) properties (MABA). In competition radioligand binding studies at human recombinant receptors, GSK-961081 displayed high affinity for hM2 (Ki = 1.4 nM), hM3 muscarinic receptors (Ki = 1.3 nM) and hß2-adrenoceptors (Ki = 3.7 nM). GSK-961081 behaved as a potent hß2-adrenoceptor agonist (EC50 = 0.29 nM for stimulation of cAMP levels) with 440- and 320-fold functional selectivity over hß1- and hß3-adrenoceptors, respectively. In guinea pig isolated tracheal tissues, GSK-961081 produced smooth muscle relaxation through MA (EC50 = 50.2 nM), BA (EC50=24.6 nM), and MABA (EC50 = 11 nM) mechanisms. In the guinea pig bronchoprotection assay, inhaled GSK-961081 produced potent, dose-dependent inhibition of bronchoconstrictor responses via MA (ED50 = 33.9 µg/ml), BA (ED50 = 14.1 µg/ml), and MABA (ED50 = 6.4 µg/ml) mechanisms. Significant bronchoprotective effects of GSK-961081 were evident in guinea pigs via MA, BA, and MABA mechanisms for up to 7 days after dosing. The lung selectivity index of GSK-961081 in guinea pigs was 55- to 110-fold greater than that of tiotropium with respect to systemic antimuscarinic antisialagogue effects and was 10-fold greater than that of salmeterol with respect to systemic ß2-adrenoceptor hypotensive effects. These preclinical findings studies suggest that GSK-961081 has the potential to be a promising next-generation inhaled lung-selective bronchodilator for the treatment of airway diseases, including chronic obstructive pulmonary disease.
Asunto(s)
Antagonistas de Receptores Adrenérgicos beta 2/farmacología , Broncodilatadores/farmacología , Carbamatos/farmacología , Antagonistas Muscarínicos/farmacología , Quinolonas/farmacología , Antagonistas de Receptores Adrenérgicos beta 2/efectos adversos , Antagonistas de Receptores Adrenérgicos beta 2/farmacocinética , Albuterol/análogos & derivados , Albuterol/farmacocinética , Albuterol/farmacología , Animales , Broncodilatadores/efectos adversos , Broncodilatadores/farmacocinética , Células CHO , Carbamatos/efectos adversos , Carbamatos/farmacocinética , Cricetinae , Cricetulus , AMP Cíclico/metabolismo , Evaluación Preclínica de Medicamentos , Cobayas , Células HEK293 , Humanos , Pulmón/efectos de los fármacos , Pulmón/fisiología , Antagonistas Muscarínicos/efectos adversos , Antagonistas Muscarínicos/farmacocinética , Relajación Muscular , Músculo Liso/efectos de los fármacos , Músculo Liso/fisiología , Unión Proteica , Quinolonas/efectos adversos , Quinolonas/farmacocinética , Receptores Adrenérgicos beta/metabolismo , Receptores Muscarínicos/metabolismo , Xinafoato de Salmeterol , Derivados de Escopolamina/farmacocinética , Derivados de Escopolamina/farmacología , Bromuro de Tiotropio , Distribución Tisular , Tráquea/efectos de los fármacos , Tráquea/fisiologíaRESUMEN
Bronchial asthma is a chronic inflammatory disorder of the airways associated with airflow obstruction that is reversible spontaneously or with treatment. Bronchial asthma is a disease based on established circadian rhythm. The symptoms of asthma worsen during midnight to early morning and therefore it is required to deliver the drug in such fashion that effective treatment can be obtained during the time of asthma attacks. Chronotherapy is an approach that fulfills the criteria of drug delivery at a specific time as per the pathophysiological need of the disease, to improve patient compliance. The current article focuses on the chronotherapy of bronchial asthma, methodologies involved for the existing systems, recent updates and different chronopharmaceutical technologies currently available in the market. Chronotherapy with different categories of bronchial asthma medications also has been reviewed.
Asunto(s)
Antiasmáticos/administración & dosificación , Asma/tratamiento farmacológico , Cronoterapia de Medicamentos , Antagonistas de Receptores Adrenérgicos beta 2/administración & dosificación , Glucocorticoides/administración & dosificación , Humanos , Antagonistas de Leucotrieno/administración & dosificación , Teofilina/administración & dosificaciónRESUMEN
We describe a label-free integrative pharmacology on-target (iPOT) method to assess the pharmacology of drugs at the ß(2)-adrenergic receptor. This method combines dynamic mass redistribution (DMR) assays using an array of probe molecule-hijacked cells with similarity analysis. The whole cell DMR assays track cell system-based, ligand-directed, and kinetics-dependent biased activities of the drugs, and translates their on-target pharmacology into numerical descriptors which are subject to similarity analysis. We demonstrate that the approach establishes an effective link between the label-free pharmacology and in vivo therapeutic indications of drugs.
Asunto(s)
Antagonistas de Receptores Adrenérgicos beta 2/farmacología , Bioensayo/instrumentación , Técnicas Biosensibles/instrumentación , Separación Celular/instrumentación , Técnicas Analíticas Microfluídicas/instrumentación , Preparaciones Farmacéuticas/administración & dosificación , Receptores Adrenérgicos beta 2/efectos de los fármacos , Evaluación Preclínica de Medicamentos/instrumentación , Diseño de Equipo , Análisis de Falla de Equipo , Citometría de Flujo/instrumentación , Mapeo de Interacción de Proteínas/instrumentación , Coloración y Etiquetado , Integración de SistemasRESUMEN
AIM: to establish a system for monitoring the activation of G-protein-coupled receptors (GPCRs) using ß-lactamase enzyme fragment complementation (EFC) technology. METHODS: two inactive ß-lactamase deletion fragments, bla(a) and bla(b), were fused to ß-arrestin and GPCR, respectively. A stable cell line named HEK/293-ß2a2, which expressed two fusion proteins, GPCR/bla(b) and ß-arrestin2/bla(a), was generated under antibiotic selection. A natural compound library of high performance liquid chromatography (HPLC)-fractionated samples from the ethanol extracts of Chinese medicinal herbs was used for high-throughput screening (HTS) of ß2-adrenoceptor (ß2AR) agonists against the cell line HEK/293-ß2a2. The interested hits were validated by the measurement of second-messenger cyclic adenosine monophosphate (cAMP) production. RESULTS: the stable cell line HEK/293-ß2a2 responded to ß2AR agonist/antagonist in a dose-dependent manner. The EC(50) value obtained for isoproterenol was 15.5 nmol/L, and the IC(50) value obtained for propranolol was 51.9 nmol/L. Furthermore, HTS was performed to identify ß2AR agonists from the natural compound library we established. The Z' factor value was determined to be 0.68. Three hits were identified from primary screening and found to be as potent as isoproterenol in a camp assay. CONCLUSION: a cell-based high-throughput functional assay was established to directly monitor the activation of GPCRs based on the interaction between agonist-activated GPCR and ß-arrestin using ß-lactamase EFC technology, which can be used to search for leads in the natural compound library.
Asunto(s)
Medicamentos Herbarios Chinos/farmacología , Receptores Acoplados a Proteínas G/agonistas , beta-Lactamasas/metabolismo , Agonistas de Receptores Adrenérgicos beta 2/farmacología , Antagonistas de Receptores Adrenérgicos beta 2/farmacología , Arrestinas/genética , Línea Celular , AMP Cíclico/metabolismo , Relación Dosis-Respuesta a Droga , Evaluación Preclínica de Medicamentos , Medicamentos Herbarios Chinos/química , Ensayos Analíticos de Alto Rendimiento , Humanos , Receptores Acoplados a Proteínas G/genética , Receptores Acoplados a Proteínas G/metabolismo , Proteínas Recombinantes de Fusión/genética , Proteínas Recombinantes de Fusión/metabolismo , Relación Estructura-Actividad , beta-Arrestinas , beta-Lactamasas/genéticaRESUMEN
In this study, we evaluated the applicability of ligand-based and structure-based models to quantitative affinity predictions and virtual screenings for ligands of the beta(2)-adrenergic receptor, a G protein-coupled receptor (GPCR). We also devised and evaluated a number of consensus models obtained through partial least square regressions, to combine the strengths of the individual components. In all cases, the bioactive conformation of each ligand was derived from molecular docking at the crystal structure of the receptor. We identified the most effective models applicable to the different scenarios, in the presence or in the absence of a training set. For ranking the affinity of closely related analogs when a training set is available, a ligand-based consensus model (LI-CM) seems to be the best choice, while the structure-based MM-GBSA score seems the best alternative in the absence of a training set. For virtual screening purposes, the structure-based MM-GBSA score was found to be the method of choice. Consensus models consistently had performances superior or close to those of the best individual components, and were endowed with a significantly increased robustness. Given multiple models with no a priori knowledge of their predictive capabilities, constructing a consensus model ensures results very close to those that the best model alone would have yielded.
Asunto(s)
Simulación por Computador , Evaluación Preclínica de Medicamentos , Receptores Adrenérgicos beta 2/química , Receptores Adrenérgicos beta 2/metabolismo , Agonistas de Receptores Adrenérgicos beta 2 , Antagonistas de Receptores Adrenérgicos beta 2 , Sitios de Unión , Cristalografía por Rayos X , Análisis Discriminante , Ligandos , Modelos Moleculares , Simulación de Dinámica Molecular , Estructura Molecular , Relación Estructura-Actividad CuantitativaRESUMEN
In this article, a single-label separation-free fluorescence technique is presented as a potential screening method for cell-based receptor antagonists and agonists.The time-resolved fluorescence technique, quenching resonance energy transfer (QRET), relies on a single-labeled binding partner in combination with a soluble quencher. The quencher efficiently suppresses the luminescence of the unbound labeled ligand, whereas the luminescence of the bound fraction is not affected. This approach allows the development of cell-based screening assays in a simple and cost-effective manner. The authors have applied the technique to the screening of beta(2)-adrenoreceptor (beta(2)AR) antagonists and agonists in intact human embryonic kidney HEK293(i) cells overexpressing human beta(2)-adrenergic receptors. Two antagonists (propranolol, alprenolol) and 2 agonists (metaproterenol, terbutaline) for beta(2)AR were investigated in a displacement assay using europium(III)-labeled pindolol ligand. The assay Z' values ranged from 0.68 to 0.78, the coefficient of variation was less than 10%, and the K(i) values were 19 nM for propranolol and alprenolol and 14 and 5.9 microM for metaproterenol and terbutaline, respectively. The QRET technique with beta(2)AR was also applied to LOPAC compound library screening, yielding nearly error-free recognition of known binders. This simple and cost-effective technique can be readily adapted to laboratory and industrial-scale screening.
Asunto(s)
Evaluación Preclínica de Medicamentos/métodos , Transferencia Resonante de Energía de Fluorescencia/métodos , Ligandos , Receptores de Superficie Celular/metabolismo , Agonistas de Receptores Adrenérgicos beta 2 , Antagonistas de Receptores Adrenérgicos beta 2 , Agonistas Adrenérgicos beta/aislamiento & purificación , Agonistas Adrenérgicos beta/farmacocinética , Antagonistas Adrenérgicos beta/aislamiento & purificación , Antagonistas Adrenérgicos beta/farmacocinética , Alprenolol/farmacocinética , Células Cultivadas , Europio/farmacocinética , Humanos , Mediciones Luminiscentes , Metaproterenol/farmacocinética , Modelos Biológicos , Propranolol/farmacocinética , Unión Proteica , Terbutalina/farmacocinéticaRESUMEN
The recently solved high-resolution X-ray structure of the beta2 adrenergic receptor has been challenged for its ability to discriminate inverse agonists/antagonists from partial/full agonists. Whereas the X-ray structure of the ground state receptor was unsuitable to distinguish true ligands with different functional effects, modifying this structure to reflect early conformational events in receptor activation led to a receptor model able to selectively retrieve full and partial agonists by structure-based virtual screening. The use of a topological scoring function based on molecular interaction fingerprints was shown to be mandatory to properly rank docking poses and achieve acceptable enrichments for partial and full agonists only.
Asunto(s)
Agonistas de Receptores Adrenérgicos beta 2 , Evaluación Preclínica de Medicamentos/métodos , Antagonistas de Receptores Adrenérgicos beta 2 , Simulación por Computador , Cristalografía por Rayos X/métodos , Isoproterenol/química , Ligandos , Modelos Moleculares , Propanolaminas/química , Relación Estructura-Actividad , Interfaz Usuario-ComputadorRESUMEN
BACKGROUND: The serotonergic 5-HT2B receptor regulates cardiomyocyte development and growth. A putative contribution of this receptor to fibroblast-dependent cardiac function has not been identified. METHODS AND RESULTS: By mimicking sympathetic stimulation with chronic isoproterenol perfusion in vivo, we found that mice developed a cardiac hypertrophy, which was prevented by exposure to the 5-HT2B receptor antagonists SB206553 or SB215505 or in 5-HT2B receptor-knockout mice. The isoproterenol-induced hypertrophy was associated with an increase in the plasma levels of interleukin-1beta and tumor necrosis factor-alpha but not interleukin-6. In contrast, the plasma isoproterenol-induced cytokine increase was not observed in either 5-HT2B receptor-mutant or wild-type mice perfused with isoproterenol+SB206553. We demonstrated that stimulation of wild-type cardiac fibroblasts by isoproterenol markedly increased the production of the interleukin-6, interleukin-1beta, and tumor necrosis factor-alpha cytokines. Strikingly, we found that this isoproterenol-induced cytokine production was abolished by SB206553 or in 5-HT2B receptor-knockout fibroblasts. Serotonin also stimulated production of the 3 cytokines in wild-type fibroblasts, which was effectively reduced in 5-HT2B receptor-knockout fibroblasts. CONCLUSIONS: Our results demonstrate for the first time that 5-HT2B receptors are essential for isoproterenol-induced cardiac hypertrophy, which involves the regulation of interleukin-6, interleukin-1beta, and tumor necrosis factor-alpha cytokine production by cardiac fibroblasts.
Asunto(s)
Cardiomegalia/fisiopatología , Fibroblastos/metabolismo , Indoles/farmacología , Indoles/uso terapéutico , Miocitos Cardíacos/citología , Piridinas/uso terapéutico , Quinolinas/farmacología , Receptor de Serotonina 5-HT2B/fisiología , Antagonistas de la Serotonina/uso terapéutico , Sistema Nervioso Simpático/fisiopatología , Antagonistas de Receptores Adrenérgicos beta 1 , Antagonistas de Receptores Adrenérgicos beta 2 , Agonistas Adrenérgicos beta/toxicidad , Animales , Cardiomegalia/inducido químicamente , Cardiomegalia/etiología , Cardiomegalia/genética , Cardiomegalia/prevención & control , Células Cultivadas/efectos de los fármacos , Células Cultivadas/metabolismo , Evaluación Preclínica de Medicamentos , Fibroblastos/efectos de los fármacos , Regulación de la Expresión Génica/efectos de los fármacos , Regulación de la Expresión Génica/fisiología , Ventrículos Cardíacos/citología , Imidazoles/farmacología , Interleucina-1/biosíntesis , Interleucina-1/sangre , Interleucina-1/genética , Interleucina-6/biosíntesis , Interleucina-6/sangre , Interleucina-6/genética , Isoproterenol/toxicidad , Ratones , Ratones Noqueados , Propanolaminas/farmacología , Piridinas/farmacología , Quinolinas/uso terapéutico , Receptor de Serotonina 5-HT2B/deficiencia , Receptor de Serotonina 5-HT2B/genética , Receptores Adrenérgicos beta 1/análisis , Receptores Adrenérgicos beta 2/análisis , Antagonistas del Receptor de Serotonina 5-HT2 , Antagonistas de la Serotonina/farmacología , Sistema Nervioso Simpático/efectos de los fármacos , Simpatomiméticos/toxicidad , Factor de Necrosis Tumoral alfa/análisis , Factor de Necrosis Tumoral alfa/biosíntesis , Factor de Necrosis Tumoral alfa/genéticaRESUMEN
OBJECTIVE: Our goal was to determine whether beta2-agonists improve the symptoms of acute bronchitis or acute cough in patients who do not have underlying pulmonary disease. STUDY DESIGN: We performed a systematic review including meta-analysis. DATA SOURCES: We included randomized controlled trials comparing beta2-agonists with placebo or alternative therapies identified from the Cochrane Library, MEDLINE, EMBASE, conference proceedings, Science Citation Index, the System for Information on Grey Literature in Europe, and letters to manufacturers of beta2-agonists. OUTCOMES MEASURED: We measured duration, persistence, severity or frequency of cough, productive cough, and night cough; duration of activity limitations; and adverse effects. RESULTS: Two trials in children with cough and no obvious airway obstruction did not find any benefits from beta2-agonists. Five trials in adults with cough and with or without airway obstruction had mixed results, but summary statistics did not reveal any significant benefits from beta2-agonists. Studies that enrolled more wheezing patients were more likely to show benefits from beta2-agonists, and in one study only patients with evidence of airflow limitation were more likely to benefit. Patients given beta2-agonists were more likely to report tremor, shakiness, or nervousness than those in the control groups. CONCLUSIONS: There is no evidence to support using beta2-agonists in children with acute cough and no evidence of airflow obstruction. There is little evidence that the routine use of beta2-agonists for adults with acute cough is helpful. These agents may reduce symptoms, including cough, in patients with evidence of airflow obstruction, but this potential benefit is not well-supported by the available data and must be weighed against the adverse effects associated with beta2-agonists.
Asunto(s)
Antagonistas de Receptores Adrenérgicos beta 2 , Agonistas Adrenérgicos beta/uso terapéutico , Bronquitis/tratamiento farmacológico , Tos/tratamiento farmacológico , Selección de Paciente , Enfermedad Aguda , Agonistas Adrenérgicos beta/efectos adversos , Adulto , Ansiedad/inducido químicamente , Bronquitis/etiología , Niño , Tos/etiología , Utilización de Medicamentos , Medicina Basada en la Evidencia , Medicina Familiar y Comunitaria/estadística & datos numéricos , Humanos , Enfermedades Pulmonares/complicaciones , Guías de Práctica Clínica como Asunto , Pautas de la Práctica en Medicina/estadística & datos numéricos , Índice de Severidad de la Enfermedad , Factores de Tiempo , Resultado del Tratamiento , Temblor/inducido químicamenteRESUMEN
OBJECTIVE: To determine: 1) if dobutamine elicited a thermogenic response during postnatal development; and 2) if this response impacted on the balance between systemic O(2) delivery (DO(2)) and O(2) consumption (VO(2)), and involved one or a combination of adrenoceptor subtypes. DESIGN: Prospective non-randomized unblinded study. SETTING: University research laboratory. SUBJECTS: Thirty-five Border-Leicester cross lambs used in a main study performed at 1-2 days (n=7), 7-10 days (n=7), and 6-8 weeks (n=8), and in a adrenoceptor blockade substudy performed at 1-2 days (n=13). INTERVENTIONS: Lambs were instrumented under anaesthesia and dobutamine was infused at incremental rates of 1-40 microg/kg per minute. In separate subgroups of 1-2 day-old lambs, dobutamine was infused after selective or combined alpha1, beta 1, and beta 2-adrenoceptor blockade. MEASUREMENTS: Cardiac output, aortic and pulmonary arterial blood gases, and body temperature were measured. DO(2) and VO(2) were calculated. MAIN RESULTS: Dobutamine increased DO(2) similarly at all three ages. Dobutamine also increased VO(2) in the absence of muscle shivering, but the average rise in 1-2 day-old lambs was sevenfold to 12-fold greater (P<0.001) than in 7-10 day-old and 6-8 week-old animals, was associated with an increase in systemic O(2) extraction, and accounted for approximately 90% of the rise in DO(2). Body temperature rose by 1.3+/-0.5 degrees C in 1-2 day-old animals (P<0.001), but was unchanged in 7-10 day-old or 6-8 week-old lambs. In 1-2 day-old lambs, rises in DO(2), VO(2), and body temperature induced by dobutamine were not affected by selective alpha1, beta1 or beta2 adrenoceptor blockade, but were markedly attenuated by combined adrenoceptor blockade. CONCLUSIONS: A substantial rise in VO(2) which accompanied a pronounced thermogenic effect of dobutamine in newborn lambs utilized most of the associated increase in DO(2) and appeared to be dependent on activation of multiple adrenoceptor subtypes.